HC Wainwright began coverage on shares of Surrozen (NASDAQ:SRZN – Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $32.00 price target on the ...

HC Wainwright reiterated their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright ...

Exodus Movement (NYSE:EXOD) is a crypto wallet company. It has been one of the most volatile names in the stock market in the ...

Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has initiated coverage on the ...

H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the previous $26.00 while continuing to endorse the stock with a Buy rating. The ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...

Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Knightscope (NasdaqCM:KSCP) with a Buy recommendation. Analyst Price Forecast Suggests 1,733.65% Upside As of January ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and $50.00 price target for Akero Therapeutics (NASDAQ:AKRO), representing significant upside potential from the current trading price of $24.01.

On Thursday, H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel ...

Rufus Wainwright’s latest classical opus, Dream Requiem, is both beautiful and grimly apposite. Originally composed during lockdown in his Laurel Canyon home while wildfires raged around him ...

On Thursday, H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing ...